Physician profile
Joseph E Mickelson
NPI 1467448043
$5,248.65
in general payments reported to CMS, 2019-2025
29 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $813 · 2021: $1,165 · 2022: $750 · 2023: $777 · 2024: $590 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,833 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,832.68 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $885.70 | 2019-2025 | Breztri, Farxiga |
| Abbvie INC. | $866.31 | 2021-2025 | |
| Glaxosmithkline, LLC. | $655.79 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $524.25 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $368.93 | 2019-2023 | Belsomra, Januvia, Steglatro |
| Novo Nordisk INC | $276.96 | 2019-2024 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $212.59 | 2020-2021 | |
| Lundbeck LLC | $199.15 | 2023-2025 | Rexulti |
| Amgen INC. | $179.50 | 2019-2025 | Otezla, Repatha, Evenity |
| Sunovion Pharmaceuticals INC. | $169.81 | 2019 | |
| Pfizer INC. | $145.16 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $114.35 | 2020-2023 | Ajovy |
| E.R. Squibb & Sons, L.L.C. | $96.82 | 2019-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $83.21 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.61 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $69.88 | 2020-2021 | |
| Insulet Corporation | $49.80 | 2023 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $41.88 | 2022-2023 | Entyvio |
| Allergan, INC. | $35.04 | 2020 | |
| Abbott Laboratories | $33.43 | 2021-2023 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $23.77 | 2023 | |
| Mylan Specialty L.P. | $22.93 | 2024 | Yupelri |
| Boston Scientific Corporation | $22.86 | 2023 | |
| Abiomed | $21.73 | 2025 | |
| Grifols USA, LLC | $17.50 | 2020 | |
| Eisai INC. | $15.78 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.71 | 2023 | |
| Biogen, INC. | $13.70 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mickelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.